» Articles » PMID: 35326625

Targeting Proliferating Tumor-Infiltrating Macrophages Facilitates Spatial Redistribution of CD8 T Cells in Pancreatic Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 25
PMID 35326625
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) play crucial roles in cancer progression, but the contributions and regulation of different macrophage subpopulations remain unclear. Here, we report a high level of TAM infiltration in human and mouse pancreatic ductal adenocarcinoma (PDAC) models and that the targeting of proliferating F4/80+ macrophages facilitated cytotoxic CD8+ T-cell-dependent antitumor immune responses. A well-defined KPC-derived PDAC cell line and the murine Panc02 PDAC cell line were used. Treatment of PDAC-bearing mice with clodronate liposomes, an agent that chemically depletes macrophages, did not impact macrophage subpopulations in the local tumor microenvironment (TME). However, further investigation using both BrdU and Ki67 to evaluate proliferating cells showed that clodronate liposomes treatment reduced proliferating macrophages in the KPC and Panc02 models. We further evaluated the distance between CD8+ T cells and PanCK+ tumor cells, and clodronate liposomes treatment significantly increased the number of CD8+ T cells in close proximity (<30 µm) to PanCK+ PDAC cells, with increased numbers of tumor-infiltrating IFN-γ+CD8+ T cells. This study suggests that targeting proliferating tumor-infiltrating macrophages may increase CD8+ cytotoxic lymphocyte (CTL) infiltration and facilitate the spatial redistribution of CD8+ T cells in tumors, contributing to the antitumor effect.

Citing Articles

Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancer.

Chen F, Onkar S, Zou J, Li Y, Arbore H, Maley S NPJ Precis Oncol. 2024; 8(1):257.

PMID: 39521942 PMC: 11550424. DOI: 10.1038/s41698-024-00746-z.


The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets.

Lorestani P, Dashti M, Nejati N, Habibi M, Askari M, Robat-Jazi B Discov Oncol. 2024; 15(1):369.

PMID: 39186144 PMC: 11347554. DOI: 10.1007/s12672-024-01256-x.


Role of Tumor-Associated Macrophages in Cervical Cancer: Integrating Classical Perspectives with Recent Technological Advances.

Choi Y, Lee D, Kim N, Seo I, Park N, Chong G Life (Basel). 2024; 14(4).

PMID: 38672714 PMC: 11051155. DOI: 10.3390/life14040443.


Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8 T cell activity.

Luan X, Lei T, Fang J, Liu X, Fu H, Li Y Mol Ther. 2023; 32(2):469-489.

PMID: 38098230 PMC: 10861991. DOI: 10.1016/j.ymthe.2023.12.010.


Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma.

Lin H, Liu Y, Caroland K, Lin J Cancers (Basel). 2023; 15(13).

PMID: 37444617 PMC: 10340421. DOI: 10.3390/cancers15133507.


References
1.
Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

2.
Feng P, Yu C, Wu C, Lee M, Lee W, Wang L . Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. Am J Transl Res. 2014; 6(5):593-603. PMC: 4212933. View

3.
Hashimoto D, Chow A, Noizat C, Teo P, Beasley M, Leboeuf M . Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013; 38(4):792-804. PMC: 3853406. DOI: 10.1016/j.immuni.2013.04.004. View

4.
Wu H, Zhang X, Han D, Cao J, Tian J . Tumour-associated macrophages mediate the invasion and metastasis of bladder cancer cells through CXCL8. PeerJ. 2020; 8:e8721. PMC: 7073239. DOI: 10.7717/peerj.8721. View

5.
Chellakkan Selvanesan B, Meena K, Beck A, Meheus L, Lara O, Rooman I . Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. J Immunother Cancer. 2020; 8(2). PMC: 7646363. DOI: 10.1136/jitc-2020-001250. View